Drug intelligence / Profile preview

TPA3

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous, Intra-arterial, Intraosseous

Overview

TPA3 is a trans-platinum planar amine carboxylate compound, part of a class of platinum-based antitumor agents. It has demonstrated cytotoxic activity and metabolic stability, outperforming cisplatin in some aspects after pre-incubation with serum. TPA3 induces DNA structural perturbation and exhibits micromolar cytotoxic activity with minimal DNA binding. In preclinical studies, TPA3 has shown prolonged survival and decreased tumor burden in a human ovarian cancer mouse model.

Targets

DNA

Beyond the preview

Go deeper on TPA3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPA3.

Explore the full profile